Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2404807 | 1.00 | EGLN2 (0.39) | EGLN2EGLN1SLC22A12SCN8ASCN10A | |
| SCHEMBL2405330 | 1.00 | EGLN2 (0.39) | EGLN2EGLN1SLC22A12SCN8ASCN10A | |
| SCHEMBL2403497 | 0.92 | SLC6A4 (0.43) | TBXA2RARSLC6A3SLC6A4KCNH2 | |
| SCHEMBL2405308 | 0.92 | SLC6A4 (0.43) | TBXA2RARSLC6A3SLC6A4KCNH2 | |
| SCHEMBL2400494 | 0.92 | SLC6A4 (0.43) | TBXA2RARSLC6A3SLC6A4KCNH2 | |
| SCHEMBL2402872 | 0.90 | AR (0.36) | SCN8ASCN10ATBXA2RARNR3C1 | |
| SCHEMBL2404848 | 0.90 | AR (0.36) | SCN8ASCN10ATBXA2RARNR3C1 | |
| SCHEMBL2404823 | 0.90 | AR (0.36) | SCN8ASCN10ATBXA2RARNR3C1 | |
| SCHEMBL15163377 | 0.89 | PPARD (0.36) | SCN8ASCN10ATBXA2RSLC6A3SLC6A4 | |
| SCHEMBL2402520 | 0.89 | PPARD (0.36) | SCN8ASCN10ATBXA2RSLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373162-B1 | AMIDOACETONITRILE COMPOUNDS AND PESTICIDAL COMPOSITION THEREOF | NOVARTIS AG (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-8168681-B2 | Amidoacetonitrile compounds and pesticidal composition thereof | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20110230563-A1 | AMIDOACETONITRILE COMPOUNDS AND PESTICIDAL COMPOSITION THEREOF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230563-A1 | AMIDOACETONITRILE COMPOUNDS AND PESTICIDAL COMPOSITION THEREOF | NAAA, PTMS, NIT2 | EGLN2 966/4885EGLN1 453/4885SLC22A12 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.